
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 February 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 220 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
Export 121 results:
Author Title Type [ Year
Filters: Author is van Staa, T. P. [Clear All Filters]
“Are inhaled corticosteroids associated with an increased risk of fracture in children?”, Osteoporos Int, vol. 15, pp. 785-91, 2004.
, “Epidemiology of childhood fractures in Britain: a study using the general practice research database”, J Bone Miner Res, vol. 19, pp. 1976-81, 2004.
, “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
, “Children and the risk of fractures caused by oral corticosteroids”, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
, “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
, “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
, “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
, “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
, “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
, “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
, “Epidemiology of fractures in England and Wales”, Bone, vol. 29, pp. 517-22, 2001.
, “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
, “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
, “Use of statins and risk of fractures”, Jama, vol. 285, pp. 1850-5, 2001.
, “Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
, “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
, “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
, “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
, “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
, “Postmarketing surveillance of the safety of cyclic etidronate”, Pharmacotherapy, vol. 18, pp. 1121-8, 1998.
, “Use of cyclical etidronate and prevention of non-vertebral fractures”, Br J Rheumatol, vol. 37, pp. 87-94, 1998.
,